

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)



(10) International Publication Number
WO 2023/035611 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/04* (2006.01)
A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/CN2022/086053

Published:
— with international search report (Art. 21(3))

(22) International Filing Date:
11 April 2022 (11.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/117692
10 September 2021 (10.09.2021) CN

(71) Applicant: SHANGHAI ALLIST PHARMACEUTI-
CALS CO., LTD. [CN/CN]; 5th Floor, Building 1, 1118
Halei Road & 1227 Zhangheng Road, Pilot Free Trade
Zone, Shanghai 201203 (CN).

(72) Inventors: LUO, Huibing; 5th Floor, Building 1, 1118
Halei Road & 1227 Zhangheng Road, Pilot Free Trade
Zone, Shanghai 201203 (CN). LI, Qing; 5th Floor, Build-
ing 1, 1118 Halei Road & 1227 Zhangheng Road, Pilot Free
Trade Zone, Shanghai 201203 (CN).

(74) Agent: CHINA PATENT AGENT (H.K.) LTD., 22/F.,
Great Eagle Centre, 23 Harbour Road, Wanchai, Hong
Kong (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PHARMACEUTICAL COMPOSITION AND USE THEREOF

(57) Abstract: The present disclosure provides a pharmaceutical composition containing a therapeutically effective amount of furmon-
ertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of said pharmaceutical
composition in manufacture of a medicament for treating and/or preventing a disease mediated by EGFR exon 20 insertion mutation.
The pharmaceutical composition of the present disclosure shows an excellent therapeutic effect on disease mediated by EGFR exon 20
insertion mutation (for example, non-small cell lung cancer (NSCLC)) with little side effects and excellent safety.

WO 2023/035611 A1